Trial Profile
IAEA-HypoX. A Randomized Multicenter Study of Accelerated Fractionated Radiotherapy With or Without the Hypoxic Radiosensitizer Nimorazole in the Treatment of Squamous Cell Carcinoma of the Head and Neck
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 28 Nov 2016
Price :
$35
*
At a glance
- Drugs Nimorazole (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Biomarker; Therapeutic Use
- 25 Jun 2012 New trial record